As Official Media Partner, VJHemOnc covered the 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL), held in Cambridge, MA, from September 6–8, 2019. This brought together world-leading researchers in lymphoma to discuss the latest data in the field.

Highlighted at the meeting this year were novel treatments in CAR T-cell therapy and the genetics underlying the prognostic features of NHL.

iwNHL 2019

06–08 September 2019 | Cambridge, Massachusetts

iwNHL 2019

06–08 September 2019 | Cambridge, Massachusetts

As Official Media Partner, VJHemOnc covered the 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL), held in Cambridge, MA, from September 6–8, 2019. This brought together world-leading researchers in lymphoma to discuss the latest data in the field.

Highlighted at the meeting this year were novel treatments in CAR T-cell therapy and the genetics underlying the prognostic features of NHL.

Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think? 15:11
Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?
John Gribben et al. • 6 Sep 2019
CAR-T for lymphoma: new targets, real world data & resistance 10:57
CAR-T for lymphoma: new targets, real world data & resistance
Barbara Savoldo et al.
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1 12:31
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1
David Weinstock et al.
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization 10:20
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
Laura Pasqualucci et al.
The need for academic and pharmaceutical collaboration in drug development 9:19
The need for academic and pharmaceutical collaboration in drug development
Jay Bradner et al.
Will knowledge of the molecular pathology of lymphoma improve clinical trials? 11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
CAR-T vs bispecific antibodies for lymphoma 12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al.
Possibilities for the use of pembrolizumab in lymphoma treatment 1:36
Possibilities for the use of pembrolizumab in lymphoma treatment
John Kuruvilla
Update on selinexor for myeloma and large cell lymphomas 2:02
Update on selinexor for myeloma and large cell lymphomas
John Kuruvilla
Developing mantle cell lymphoma treatment for further success 1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals